Pancreatic cancer is one of the most aggressive cancers and five-year survival rates are just 10%. A very small number of patients live longer, with less than 2% surviving more than 10 years after diagnosis. Researchers have been working to understand how this cancer...

The Avner Australian Pancreatic Cancer Matrix Atlas group (APMA) will investigate a potential new way to improve immunotherapy outcomes for patients with pancreatic cancer using a class of drug that can reduce the metabolic rewiring of the cancer cells thanks to a...

November is recognised as World Pancreatic Cancer Awareness Month. We take time to raise awareness of the disease, celebrate survivors and acknowledge pancreatic cancer research.     Pancreatic cancer has now become the third leading cause of cancer deaths...